Expect major updates on their clinical pipeline momentum, including:
* The pivotal Phase III MAVERIC trial for recurrent pericarditis
* Newly published Phase II ARCHER results in acute myocarditis
* The next-gen drug CRD-38 in development for heart failure
Set your reminders and tune in at http://x.com/Barchart!
#StockOnHighAlert #FrontPageStocks #CRDL #Biotech #Investing #CardiolRx #WallStreet